Suppr超能文献

间充质干细胞及其外泌体对巨大难治性黄斑裂孔愈合的影响。

Effects of mesenchymal stem cells and their exosomes on the healing of large and refractory macular holes.

作者信息

Zhang Xiaomin, Liu Juping, Yu Bo, Ma Feifei, Ren Xinjun, Li Xiaorong

机构信息

Department of Uveitis & Ocular Immunology, Tianjin Medical University Eye Hospital, Eye Institute & School of Optometry and Ophthalmology, Tianjin, China.

Laboratory of Stem Cells, Tianjin Medical University Eye Hospital, Eye Institute & School of Optometry and Ophthalmology, Tianjin, China.

出版信息

Graefes Arch Clin Exp Ophthalmol. 2018 Nov;256(11):2041-2052. doi: 10.1007/s00417-018-4097-3. Epub 2018 Aug 30.

Abstract

PURPOSE

To assess the efficacy of mesenchymal stem cells (MSCs) and MSC-derived exosomes (MSC-Exos) to promote the healing of large and refractory macular holes (MHs).

METHODS

Seven patients (age 51-75 years old) with large and long-standing idiopathic MHs underwent vitrectomy, internal limiting membrane peeling, MSC (two patients) or MSC-Exo (five patients) intravitreal injection, and heavy silicon oil, air, 20% SF6, or 14% C3F8 tamponade. The MSCs were isolated from human umbilical cord tissue, and MSC-Exos were isolated from the supernatants of cultured MSCs using sequential ultracentrifugation.

RESULTS

Five eyes underwent pars plana vitrectomy (PPV) only, while two underwent PPV combined with cataract surgery. Six MHs were closed, while one remained in a flat-open state. The best-corrected visual acuity (BCVA) was improved in five patients with MH closure and remained unchanged in one patient with MH closure who had a 4-year history of MH. A fibrotic membrane was observed on the surface of the retina in one patient who underwent MSC therapy. One patient who received a higher dose of MSC-Exos exhibited an inflammatory reaction.

CONCLUSIONS

MSC and MSC-Exo therapy may promote functional and anatomic recovery from MH. MSC-Exo therapy may be a useful and safe method for improving the visual outcomes after surgery for refractory MHs.

摘要

目的

评估间充质干细胞(MSCs)和间充质干细胞衍生的外泌体(MSC-Exos)促进大的难治性黄斑裂孔(MHs)愈合的疗效。

方法

7例年龄在51 - 75岁的大的长期特发性MHs患者接受了玻璃体切除术、内界膜剥除术,2例患者玻璃体内注射MSCs,5例患者玻璃体内注射MSC-Exos,并用重硅油、空气、20%的六氟化硫或14%的八氟丙烷进行填塞。MSCs从人脐带组织中分离,MSC-Exos通过连续超速离心从培养的MSCs的上清液中分离。

结果

5只眼仅接受了经睫状体平坦部玻璃体切除术(PPV),2只眼接受了PPV联合白内障手术。6个MHs闭合,1个仍处于扁平开放状态。5例MH闭合患者的最佳矫正视力(BCVA)得到改善,1例有4年MH病史的MH闭合患者的视力保持不变。1例接受MSC治疗的患者视网膜表面观察到纤维化膜。1例接受较高剂量MSC-Exos的患者出现炎症反应。

结论

MSC和MSC-Exo治疗可能促进MH的功能和解剖恢复。MSC-Exo治疗可能是一种改善难治性MHs手术后视力预后的有用且安全的方法。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验